IGHE and allergic disease: For example, it can perpetuate the lack of access to allergy-specific techniques (eg, ST, specific IgE, or basophil activation test), to clinical expertise in overall drug allergy and risk-assessment (eg, adequate endophenotyping), or to additional therapeutic options (eg, omalizumab as a premedication), which would be widely available to allergy-led teams.2